Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

49.85 -0.55 (-1.09%)
Streaming Delayed Price Updated: 3:59 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
36 37 Next >
News headline image
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates ↗
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were... 
Via Benzinga
News headline image
Healthcare Stocks Are Winners And Provide Diversification To Your Portfolio ↗
As we have written their year many times speculative small cap biotechs have not done well in 2021 since they peaked in February. 
Via Talk Markets
News headline image
Boxing Day Finance ↗
Today we saw the Dow Jones move up over 36,000. 
Via Talk Markets
News headline image
Free COVID Tests: What Stocks Will Benefit? ↗
The government hasn’t announced yet what company or companies it will be buying from, but there are several businesses involved in producing these kits. 
Via Talk Markets
News headline image
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot ↗
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
News headline image
Dreaming Of A Red Christmas ↗
The stock market is reacting with lots of selling to the weekend's news. 
Via Talk Markets
News headline image
Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases ↗
Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC: RHHBY)... 
Via Benzinga
News headline image
Raising Rates ↗
The Bank of England raised its interest rate to 0.25%, setting a pattern for other countries. 
Via Talk Markets
News headline image
These OTC Securities Had the Most Trading Activity in November ↗
Photo by Markus Winkler on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug... 
Via Benzinga
News headline image
Novartis Launches New Share Buyback Program Of Up To $15B ↗
Novartis AG (NYSE: NVS) is launching a new share buyback worth up to $15 billion to be executed by the end of 2023, adding it was confident in its top-line growth... 
Via Benzinga
News headline image
After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial ↗
Atea Pharmaceuticals Inc (NASDAQ: AVIR) said it would close the global Phase 3 MORNINGSKY trial. The decision comes after considering the changing COVID-19 landscape... 
Via Benzinga
News headline image
Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients ↗
Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 POLARIX study of Polivy (polatuzumab vedotin) with MabThera/Rituxan (rituximab) and the chemotherapy regimen... 
Via Benzinga
News headline image
Genentech’s Polivy Combination Reduced the Risk of Disease Worsening or Death by 27% in People With Previously Untreated Aggressive Form of Lymphoma
From Genentech
Via Business Wire
News headline image
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that... 
Via Benzinga
News headline image
Biotech Playbook 2021: No Help From Small Caps In Q4 ↗
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but... 
Via Talk Markets
News headline image
Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings ↗
Roche Holdings AG's (OTC: RHHBY) mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells, posted a 60%... 
Via Benzinga
News headline image
Interim Data From Phase III HAVEN 6 Study Demonstrate Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A
From Genentech
Via Business Wire
News headline image
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More ↗
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple... 
Via Benzinga
News headline image
Genentech Presents Pivotal Data at ASH 2021 for Novel Cancer Immunotherapy Mosunetuzumab
From Genentech
Via Business Wire
News headline image
Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial ↗
Infinity Pharmaceuticals Inc (NASDAQ: INFI) presented updated data from the ongoing MARIO-3 study during the 2021 San Antonio Breast Cancer Symposium (SABCS).... 
Via Benzinga
News headline image
Roche Posts Encouraging Follow-up Data From Tiragolumab/Tecentriq Trial In Lung Cancer ↗
Roche Holdings AG (OTC: RHHBY) reported follow-up efficacy, safety, and patient-reported outcomes data from the Phase 2 CITYSCAPE trial of tiragolumab plus... 
Via Benzinga
News headline image
New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentech’s Novel Anti-TIGIT Tiragolumab Plus Tecentriq
From Genentech
Via Business Wire
News headline image
Wednesday Global Investing Report ↗
Between the Amazon Cloud issues and the clouds gathering over the Ukraine border, it's getting harder to tell exactly what's happening to markets. Here are some insights into the international... 
Via Talk Markets
News headline image
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts ↗
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. 
Via InvestorPlace
News headline image
Europe Approves Roche's Tocilizumab For Patients With Severe COVID-19 ↗
The European Commission has extended the marketing authorization for Roche Holdings AG's (OTC: RHHBY) Actemra/RoActemra (Tocilizumab) to treat patients with severe... 
Via Benzinga
News headline image
recession in 2022? ↗
China has cut its reserve requirement for lending by 50% giving a $188 bn boost to its market. 
Via Talk Markets
Topics Economy
News headline image
How Did Healthcare Stocks Perform Over This Volatile Month? ↗
It’s been a rough month for small-cap biotech stocks amidst a general correction in the market which brought general indices down about 10%. 
Via Talk Markets
News headline image
Immunocore' ImmTAC Candidate Shows Early Response In Ovarian And Head & Neck Cancer Patients ↗
Immunocore Holdings Plc (NASDAQ: IMCR) announced the initial Phase 1 data of IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in selected advanced solid... 
Via Benzinga
News headline image
Charms Of China ↗
Today the global stock market rout was pretty awful. 
Via Talk Markets
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.